Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1387-1392

  Skov, Vibe ^a   Larsen, Thomas Stauffer ^a   Thomassen, Mads ^a   Riley, Caroline Hasselbalch ^b   Jensen, Morten K ^b   Bjerrum, Ole Weis ^b   Kruse, Torben A ^a   Hasselbalch, Hans Carl ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Immunoregulation; Inflammation; Microarray; Philadelphia negative chronic myeloproliferative neoplasms; Whole blood gene expression profiling

Indexed keywords

CD40 LIGAND; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; COMPLEMENT COMPONENT C5; CXCL9 CHEMOKINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 17; INTERLEUKIN 5; PENTRAXIN 3; PROTEIN BCL 6; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A;

ARTICLE; CD34 SELECTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GRANULOCYTE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYELOID METAPLASIA; PERIPHERAL BLOOD STEM CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; UPREGULATION;

BLOOD CELLS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFLAMMATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; TRANSCRIPTOME;

EID: 84866332049     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.009     Document Type: Article

References (50)

1. Campbell P.J., Green A.R. Mechanisms of disease. The myeloproliferative disorders. N Engl J Med 2006, 355(23):2452-2466.
2. Kristinsson S.Y., Landgren O., Samuelsson J., Björkholm M., Goldin L.R. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010, 95(July (7)):1216-1220.
3. Pellagatti A., Vetrie D., Langford C.F., Gama S., Eagleton H., Wainscoat J.S., et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res 2003, 63:3940-3944.
4. Goerttler P.S., Kreutz C., Donauer J., Faller D., Maiwald T., März E., et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 2005, 129:138-150.
5. Jones L.C., Tefferi A., Vuong P.T., Desmond J.C., Hofmann W.K., Koeffler H.P. Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells 2005, 23:631-637.
6. Guglielmelli P., Zini R., Bogani C., Salati S., Pancrazzi A., Bianchi E., et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells 2007, 25:165-173.
7. Catani L., Zini R., Sollazzo D., Ottaviani E., Vannucchi A.M., Ferrari S., et al. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia 2009, 23:997-1000.
8. Berkofsky-Fessler W., Buzzai M., Kim M.K., Fruchtman S., Najfeld V., Min D.J., et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 2010, 16(17):4339-4352.
9. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Whole blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 2011, 87(1):54-60.
10. Hasselbalch H.C., Skov V., Larsen T.S., Riley C.H., Thomassen M., Jensen M.K., et al. High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leuk Res 2011, 35(10):1330-1334.
11. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 2012, 53(1):123-129.
12. Skov V., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., Kruse T.A., et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 2012, [Epub ahead of Print].
13. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
14. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article 3.
15. Imai Y., Nara N., Tohda S., Nagata K., Suzuki T., Nagasawa M., et al. Antiproliferative and differentiative effects of recombinant interleukin-4 on a granulocyte colony-stimulating factor-dependent myeloblastic leukemic cell line. Blood 1991, 78(2):471-478.
16. Pieri A., Bogani C., Guglielmelli P., Zingariello M., Rana R.A., Barttalucci N., et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 2009, 94(11):1537-1545.
17. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991, 174:1549-1555.
18. Ohmori Y., Hamilton T.A. Regulation of macrophage gene expression by T cell derived lymphokines. Pharmacol Ther 1994, 63:235-264.
19. Johnson B.F., Osada T., Clay T.M., Lyerly H.K., Morse M.A. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 2009, 9(6):702-707.
20. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31(6):220-227.
21. Lee J.C., Lee K.M., Ahn Y.O., Suh B., Heo D.S. A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1. Tumori 2011, 97(3):350-357.
22. Wada J., Suzuki H., Fuchino R., Yamasaki A., Nagai S., Yanai K., et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 2009, 29(3):881-888.
23. Kushwah R., Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci 2011, 1(1):20.
24. Théroux P., Martel C. Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol 2006, 22(February (Suppl. B)):18B-24B.
25. Barbui T., Carobbio A., Finazzi G., Vannucchi A.M., Barosi G., Antonioli E., et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C reactive protein and pentraxin 3. Haematologica 2011, 96(February (2)):315-318.
26. Quist-Paulsen P., Naess I.A., Cannegieter S.C., Romundstad P.R., Christiansen S.C., Rosendaal F.R., et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010, 95(1):119-125.
27. Norata G.D., Marchesi P., Pulakazhi Venu V.K., Pasqualini F., Anselmo A., Moalli F., et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120(8):699-708.
28. Carobbio A., Antonioli E., Guglielmelli P., Vannucchi A.M., Delaini F., Guerini V., et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008, 26(16):2732-2736.
29. Carobbio A., Thiele J., Passamonti F., Rumi E., Ruggeri M., Rodeghiero F., et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011, 117(22):5857-5859.
30. Di Raimondo F., Azzaro M.P., Palumbo G.A., Bagnato S., Stagno F., Giustolisi G.M., et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001, 15(6):976-980.
31. Medinger M., Skoda R., Gratwohl A., Theocharides A., Buser A., Heim D., et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009, 146(2):150-157.
32. Le Bousse-Kerdilès M.C., Martyré M.C. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999, 78(10):437-444.
33. Dong M., Blobe G.C. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006, 107(12):4589-4596.
34. Theilgaard-Monch K., Jacobsen L.C., Borup R., Rasmussen T., Bjerregaard M.D., Nielsen F.C., et al. The transcriptional program of terminal granulocytic differentiation. Blood 2005, 105:1785-1796.
35. Riley C.H., Jensen M.K., Brimnes M.K., Hasselbalch H.C., Bjerrum O.W., Straten P.T., et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with interferon-alpha. Blood 2011, 118(8):2170-2173.
36. Müller C.I., Quang T., Luong Q.T., Jones L.C., Desmond J.C., Kawamata N., et al. Reduced expression of ADAM8 is associated with myelofibrosis in myeloproliferative disease. AACR Meeting Abstract #115. Proc Am Assoc Cancer Res 2006, 47.
37. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011, 29(10):1356-1363.
38. Panteli K.E., Hatzimichael E.C., Bouranta P.K., Katsaraki A., Seferiadis K., Stebbing J., et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005, 130(5):709-715.
39. Boissinot M., Cleyrat C., Vilaine M., Jacques Y., Corre I., Hermouet S. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. Oncogene 2011, 30(8):990-1001.
40. Campanelli R., Rosti V., Villani L., Castagno M., Moretti E., Bonetti E., et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine 2011, 53(1):100-106.
41. Coudriet G.M., He J., Trucco M., Mars W.M., Piganelli J.D. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS One 2010, 5(11):e15384.
42. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
43. Hasselbalch H.C. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2012, 119(14):3219-3225.
44. Vannucchi A.M. From palliation to targeted therapy in myelofibrosis. N Engl J Med 2010, 363(12):1180-1182.
45. Rambaldi A., Dellacasa C.M., Finazzi G., Carobbio A., Ferrari M.L., Guglielmelli P., et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010, 150(4):446-455.
46. Fleischman A.G., Aichberger K.J., Luty S.B., Bumm T.G., Petersen C.L., Doratotaj S., et al. Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011, 118(24):6392-6398.
47. Hermouet S., Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?. Haematologica 2011, 96(11):1575-1579.
48. Frederiksen H., Farkas D.K., Christiansen C.F., Hasselbalch H.C., Sørensen H.T. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011, 118(25):6515-6520.
49. Kiladjian J.J., Mesa R.A., Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011, 117(18):4706-4715.
50. Hasselbalch H.C. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011, 4(6):637-655.